Literature DB >> 19052529

Progress in global measles control and mortality reduction, 2000-2007.

.   

Abstract

Despite the availability of a safe and effective vaccine since 1963, measles has been a major killer of children in developing countries (causing an estimated 750,000 deaths as recently as 2000), primarily because of underutilization of the vaccine. At the World Health Assembly in 2008, all World Health Organization (WHO) member states reaffirmed their commitment to achieving a 90% reduction in measles mortality by 2010 compared with 2000, a goal that was established in 2005 as part of the Global Immunization Vision and Strategy (2). This WHO-UNICEF comprehensive strategy for measles mortality reduction (1) focuses on 47 priority countries. The strategy's components include 1) achieving and maintaining high coverage (>90%) with the routinely scheduled first dose of measles-containing vaccine (MCV1) among children aged 1 year; 2) ensuring that all children receive a second opportunity for measles immunization (either through a second routine dose or through periodic supplementary immunization activities [SIAs]); 3) implementing effective laboratory-supported disease surveillance; and 4) providing appropriate clinical management for measles cases. This report updates previously published reports and describes immunization and surveillance activities implemented during 2007. Increased routine measles vaccine coverage and SIAs implemented during 2000--2007 resulted in a 74% decrease in the estimated number of measles deaths globally. An estimated 197,000 deaths from measles occurred in 2007; of these, 136,000 (69%) occurred in the WHO South-East Asian Region. Achievement of the 2010 goal will require full implementation of measles mortality reduction strategies, especially in the WHO South-East Asian Region.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19052529

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  12 in total

1.  Seroprevalence of measles, mumps and rubella among young adults, after 20 years of universal 2-dose MMR vaccination in Israel.

Authors:  Hagai Levine; Salman Zarka; Omer E Ankol; Vladi Rozhavski; Nadav Davidovitch; Yair Aboudy; Ran D Balicer
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Broadly neutralizing immune responses against hepatitis C virus induced by vectored measles viruses and a recombinant envelope protein booster.

Authors:  Jorge Reyes-del Valle; Cynthia de la Fuente; Mallory A Turner; Christoph Springfeld; Swapna Apte-Sengupta; Marie E Frenzke; Amelie Forest; Jillian Whidby; Joseph Marcotrigiano; Charles M Rice; Roberto Cattaneo
Journal:  J Virol       Date:  2012-08-15       Impact factor: 5.103

3.  A large observational study to concurrently assess persistence of measles specific B-cell and T-cell immunity in individuals following two doses of MMR vaccine.

Authors:  Iana H Haralambieva; Inna G Ovsyannikova; Megan O'Byrne; V Shane Pankratz; Robert M Jacobson; Gregory A Poland
Journal:  Vaccine       Date:  2011-05-01       Impact factor: 3.641

4.  Quantifying child mortality reductions related to measles vaccination.

Authors:  Jeremy D Goldhaber-Fiebert; Marc Lipsitch; Ajay Mahal; Alan M Zaslavsky; Joshua A Salomon
Journal:  PLoS One       Date:  2010-11-04       Impact factor: 3.240

5.  Newly identified minor phosphorylation site threonine-279 of measles virus nucleoprotein is a prerequisite for nucleocapsid formation.

Authors:  Akihiro Sugai; Hiroki Sato; Kyoji Hagiwara; Hiroko Kozuka-Hata; Masaaki Oyama; Misako Yoneda; Chieko Kai
Journal:  J Virol       Date:  2013-11-06       Impact factor: 5.103

Review 6.  Measles control--can measles virus inhibitors make a difference?

Authors:  Richard K Plemper; James P Snyder
Journal:  Curr Opin Investig Drugs       Date:  2009-08

7.  Common genes for non-syndromic deafness are uncommon in sub-Saharan Africa: a report from Nigeria.

Authors:  Akeem O Lasisi; Guney Bademci; Joseph Foster; Susan Blanton; Mustafa Tekin
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2014-08-23       Impact factor: 1.675

8.  Contribution of matrix, fusion, hemagglutinin, and large protein genes of the CAM-70 measles virus vaccine strain to efficient growth in chicken embryonic fibroblasts.

Authors:  Luna Bhatta Sharma; Shinji Ohgimoto; Seiichi Kato; Sekiko Kurazono; Minoru Ayata; Kaoru Takeuchi; Toshiaki Ihara; Hisashi Ogura
Journal:  J Virol       Date:  2009-09-02       Impact factor: 5.103

9.  Target analysis of the experimental measles therapeutic AS-136A.

Authors:  Jeong-Joong Yoon; Stefanie A Krumm; J Maina Ndungu; Vanessa Hoffman; Bettina Bankamp; Paul A Rota; Aiming Sun; James P Snyder; Richard K Plemper
Journal:  Antimicrob Agents Chemother       Date:  2009-06-15       Impact factor: 5.191

10.  RIG-I is required for the inhibition of measles virus by retinoids.

Authors:  Kaitlin J Soye; Claire Trottier; Chris D Richardson; Brian J Ward; Wilson H Miller
Journal:  PLoS One       Date:  2011-07-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.